For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.

Lori Gavrin

Lori Gavrin has 16 years of experience working in the field of drug discovery and development. Lori graduated as a Summa Cum Laude chemistry major from Colgate University and subsequently completed her PhD in organic chemistry at the University of Pennsylvania under the guidance of Professor Jeffrey Winkler.

Lori then moved to Wyeth / Pfizer, where she practiced medicinal chemistry for 12 years. During this time, she gained broad drug discovery experience working on projects from target identification to clinical candidate selection, spanning multiple therapeutic areas including rare diseases, neuroscience, immuno-inflammation, metabolic disease and women’s health. She made significant scientific contributions and designed two compounds that entered clinical development.

In 2013, Lori was accepted into the highly selective R&D Esprit Leadership Development Program at GlaxoSmithKline. This is a 3-year rotational program specifically designed to develop GSK’s next generation of high performance scientific leaders. Whilst in the Esprit program, Lori successfully championed work streams in three diverse R&D teams: Strategy and Portfolio, Maternal & Neonatal Health, and Discovery Partnerships with Academia. Lori’s current role is Director of Business Development for the Platform & Technology Sciences Division at GSK, where she leads the external strategy for small molecule platform technology licensing. She is also a passionate supporter of increasing interactions between pharma, biotech and academia.

Lori recently co-chaired the ACSMEDI-EFMC Frontiers in Medicinal Chemistry Symposium, chaired the 2015 Medicinal Chemistry Gordon Research Conference and sits on the Long Range Planning Committee for the ACS MEDI Division. Lori serves on the Scientific Advisory Boards of the Chemistry Department at the University of Pennsylvania, the BioStrategy Partners Organization and the Coulter Translational Drug Discovery Program at Drexel University. She has authored more than a dozen publications and is a named inventor on 11 patents.